Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amneal’s Chirag Patel Chairs AAM Board

Replaces Lupin’s Alok Sonig As US Association Announces Fresh Leadership

Executive Summary

Amneal president and co-CEO Chirag Patel has been named as chair of the AAM’s board of directors, as the US generics and biosimilars industry association unveiled leadership changes on the first day of its Access! 2022 annual meeting.

You may also be interested in...



AAM Names Teva’s Baeder Chair As It Kicks Off Annual Meeting

Christine Baeder has become chair of the AAM’s board, with the Teva executive welcomed to role as the US industry association kicked off its annual Access! conference in Orlando.

Teva’s Baeder: We Need To ‘Crack The Nut’ Of Complex Generics

Industry and regulators need to collaborate to provide complex generics with the opportunity to build even further on the significant contributions already made by off-patent medicines to savings and access, Christine Baeder, senior vice president and chief operating officer of Teva’s US generics division, tells Generics Bulletin in the first part of an exclusive interview.

AAM Reshuffles Board For 2021

US off-patent industry association the AAM has announced a fresh board of directors and officers for 2021, reflecting local management changes at multiple leading generics and biosimilars firms.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB151646

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel